Syndax Pharmaceuticals/$SNDX
Syndax shares fall after axatilimab failed the Phase 2 MAXPIRe trial’s primary endpoint in idiopathic pulmonary fibrosis, prompting the company to halt development for that condition.
2 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
- Ticker
- $SNDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 298
- Headquarters
- New York, United States
- Website
- syndax.com
SNDX Metrics
BasicAdvanced
$1.5B
-
-$2.51
0.37
-
Price and volume
Market cap
$1.5B
Beta
0.37
52-week high
$25.59
52-week low
$12.99
Average daily volume
1.8M
Financial strength
Current ratio
6.772
Quick ratio
6.291
Long term debt to equity
39.001
Total debt to equity
39.035
Interest coverage (TTM)
-4.58%
Profitability
EBITDA (TTM)
-194.16
Gross margin (TTM)
-8.01%
Net profit margin (TTM)
-87.52%
Operating margin (TTM)
-76.98%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-18.67%
Return on equity (TTM)
-255.93%
Valuation
Price to revenue (TTM)
5.761
Price to book
97.72
Price to tangible book (TTM)
97.72
Price to free cash flow (TTM)
-6.58
Free cash flow yield (TTM)
-15.20%
Free cash flow per share (TTM)
-2.515
Growth
Revenue change (TTM)
223.68%
Earnings per share change (TTM)
-35.36%
10-year revenue growth (CAGR)
70.43%
3-year earnings per share growth (CAGR)
0.99%
10-year earnings per share growth (CAGR)
-16.60%
What the Analysts think about SNDX
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
Analyst projections of the future price of Syndax Pharmaceuticals stock.
Bulls say / Bears say
Revuforj generated $54.7 million in second-quarter 2026 net revenue, up 91% year on year, while prescriptions rose 121%. Longer treatment duration is also supporting growth, giving Syndax a rapidly expanding commercial base in acute leukaemia. (Syndax Pharmaceuticals)
Niktimvo sales reached about $60 million in the second quarter, up 67% year on year, with uptake growing in later treatment lines. It gives Syndax a second commercial growth driver alongside Revuforj. (Syndax Pharmaceuticals)
In the early-stage SAVE study, a revumenib combination produced an 88% overall response rate, and 80% of evaluable patients who achieved a composite remission were measurable-residual-disease negative. These results offer clinical support for testing the drug in further acute leukaemia settings, though they are not pivotal-trial evidence. (GlobeNewswire)
Axatilimab failed to meet the primary endpoint in its Phase 2 idiopathic pulmonary fibrosis trial, and Syndax has stopped development for that disease. This removes a substantial potential expansion opportunity for Niktimvo. (BioSpace)
Syndax expects about $400 million of 2026 research and selling expenses, before roughly $50 million of stock compensation. The company therefore needs continued revenue growth to absorb a substantial cost base and reach profitability. (Syndax Pharmaceuticals)
Commercial growth currently rests on Revuforj and Niktimvo, leaving the business exposed if either product’s uptake disappoints. The company’s other cited programmes remain in development, so they do not yet provide a proven alternative revenue base. (Syndax Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
SNDX Financial Performance
Revenues and expenses
SNDX Earnings Performance
Company profitability
Upcoming events
No upcoming events
SNDX News
AllArticlesVideos
Funds containing SNDX
AllUSDEURGBP
Fund name | Fund size | $SNDX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.14% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.14% |
iShares Healthcare Innovation£DRDR | £1B | 0.14% |
iShares Ageing Population$AGED | $953M | 0.13% |
iShares Ageing Population€AGED | €822M | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.